UNASSIGNED: In the present study, the dosage and duration of rasburicase administration were retrospectively evaluated for the ability to control the serum @entity414 (S-UA) level in 13 @entity1 diagnosed with @entity1583 and @entity5405 ( @entity5405 ), or those at risk of developing @entity5405 , at the University of Fukui Hospital. At the time of diagnosis, seven @entity1 already exhibited laboratory @entity5405 , and three demonstrated clinical @entity5405 . All @entity1 received rasburicase in addition to chemotherapy agents. The median dose was 0.19 mg/kg (range, 0.13-0.25 mg/kg), and the median duration was four days (range, 1-7 days). Six @entity1 sequentially received a @entity3624 oxidase inhibitor, @entity208 or @entity20082 . The primary estimate was the normalization of the S-UA level at the end of rasburicase treatment and on treatment day seven. The average S-UA level prior to treatment was 10.4  4.5 mg/dl (mean   standard deviation), and 11 out of 13 @entity1 demonstrated a S-UA level >7 mg/dl. The S-UA level at the end of rasburicase administration was 0.5  1.5 mg/dl and the S-UA level at day seven was 1.4  1.5 mg/dl. All the @entity1 achieved normalization of the S-UA level. On day seven subsequent to the initiation of treatment, the @entity1 receiving rasburicase for a maximum of three days exhibited an S-UA level of 1.9  1.8 mg/dl, while the @entity1 receiving rasburicase for longer than three days demonstrated an S-UA level of 1.0  1.3 mg/dl (P=0.20; Mann-Whitney test). The administration of 0.13 mg/kg and 0.22 mg/kg resulted in comparable UA level reductions. The administration of @entity208 or @entity20082 following rasburicase administration suppressed the re-increase in S-UA level. Therefore, it was concluded that reduced administration of rasburicase successfully controlled the S-UA level in @entity5405 .

Reduced administration of rasburicase for XXXX : A single-institution experience.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5405 :: ('MESH:D015275', 'Disease') :: ['TLS', 'tumor lysis syndrome'] @entity3624 :: ('MESH:D019820', 'Chemical') :: ['xanthine'] @entity20082 :: ('MESH:C084623', 'Chemical') :: ['febuxostat'] @entity1583 :: ('MESH:D019337', 'Disease') :: ['hematological malignancies'] @entity208 :: ('MESH:D000493', 'Chemical') :: ['allopurinol'] @entity414 :: ('MESH:D014527', 'Chemical') :: ['uric acid']
@entity5405 :: (MESH:D015275,Disease) :: ['tumor lysis syndrome']
